Aromataz inhibitörü Bazlı adjuvan terapi ile tedavi edilen hastalarda CYP19A1 genetik polimorfizmi rs4646 ve Osteoporoz

Translated title of the contribution: CYP19A1 genetic polymorphisms RS4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy

Federica Mazzuca, Andrea Botticelli, Eva Mazzotti, Marco La Torre, Marina Borro, Luca Marchetti, Chiara Maddalena, Giovanna Gentile, Maurizio Simmaco, Paolo Marchetti

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes. Materials and Methods: Forty-five postmenopausal breast cancer patients (46-85 yrs) in AI adjuvant treatment were genotyped for the rs4646 polymorphisms of CYP19A1 gene and three variations were identified. Toxicities were registered at each follow-up medical examination, and classified in accord with the Common Terminology Criteria for Adverse Events. Results: Twenty-four (53.3%) patients presented the GG genotype; 19 (42.2%) the GT, and 2 (4.4%) the TT. The AI treatment was Anastrazole for 35 patients (77.8%) and Letrozole for the others (n=10; 22.2%). Osteoporosis was significantly associated with the GG genotype (p=0.001). Treatment discontinuation (TD) was observed in 6 cases (13.3%). The only parameter able to predict TD was the appearance of severe arthralgia/myalgia (Odds Ratio, OR=23.75; p=0.009), when adjusted for age and AI treatment. Conclusion: Our results suggest that CYP19A1 polymorphic variants may influence susceptibility to develop AI-related side effects. Further prospective studies are needed to confirm the role of the aromatase gene (CYP19A1) polymorphisms in predicting adverse effects to AI-based therapy.

Translated title of the contributionCYP19A1 genetic polymorphisms RS4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy
Original languageTurkish
Pages (from-to)10-14
Number of pages5
JournalEurasian Journal of Medicine
Volume48
Issue number1
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • Adjuvant hormonal therapy
  • Aromatase inhibitor
  • Breast cancer
  • CYP19A1
  • rs4646
  • Single nucleotide polymorphisms

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'CYP19A1 genetic polymorphisms RS4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy'. Together they form a unique fingerprint.

Cite this